Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

NCT00290953 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Pulmonary Neoplasms
Small Cell Lung Cancer

Interventions

DRUG: SR48692

Sponsor

Sanofi